How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Short Bowel Syndrome Market
- By Treatment Type: Parenteral Nutrition, Enteral Nutrition, Pharmacological Therapy, Surgical Interventions, Intestinal Transplantation
- By Cause of Short Bowel Syndrome: Crohn's Disease, Mesenteric Ischemia, Trauma or Surgical Resection, Congenital Defects, Radiation Enteritis
- By Patient Age Group: Pediatric, Adult, Geriatric
- By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Home Healthcare Settings, Retail Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Parenteral Nutrition leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 274 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.165 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.173 →
Full report · locked preview
Everything inside the Short Bowel Syndrome Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Cause of Short Bowel Syndrome 5
Patient Age Group 3
Distribution Channel 4
Companies profiled
Takeda Pharmaceutical Company Limited
Fresenius Kabi
Nestlé Health Science
AbbVie Inc.
Baxter International Inc.
Mallinckrodt Pharmaceuticals
Vifor Pharma
Sandoz (a Novartis division)
Amgen Inc.
Helsinn Group
Norgine B.V.
Viatris Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Takeda Pharmaceutical Company Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Nestlé Health Science
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Mallinckrodt Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Vifor Pharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sandoz (a Novartis division)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Amgen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Helsinn Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Norgine B.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Viatris Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Shire (now part of Takeda)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sandoz
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Baxter
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,178M by 2033 · 10.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Parenteral Nutrition52.8
- Enteral Nutrition11.1
- Pharmacological Therapy17.7
- Surgical Interventions9.4
- Intestinal Transplantation8.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,645M → $3,781M · 11.0%
Europe$1,146M → $2,420M · 9.8%
Asia Pacific$1,047M → $2,354M · 10.7%
Latin America$648.0M → $1,343M · 9.5%
Middle East and Africa$498.5M → $1,118M · 10.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.582026
10.582027
10.602028
10.612029
10.632030
10.632031
10.652032
10.662033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Takeda Pharmaceutical Company Limited21.8
- Fresenius Kabi13.4
- Nestlé Health Science10.7
- AbbVie Inc.10.4
- Baxter International Inc.11.2
- Mallinckrodt Pharmaceuticals4.6
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type17.0%
Cause of Short Bowel Syndrome36.6%
Patient Age Group30.0%
Distribution Channel16.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.3
- Europe22.0
- Asia Pacific21.4
- Latin America12.2
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited | 89 | 96 | 95 | 93 | 96 | 79 | 91 |
| Fresenius Kabi | 70 | 76 | 75 | 85 | 83 | 77 | 78 |
| Nestlé Health Science | 76 | 66 | 72 | 78 | 73 | 84 | 75 |
| AbbVie Inc. | 68 | 72 | 58 | 64 | 68 | 79 | 68 |
| Baxter International Inc. | 55 | 62 | 69 | 67 | 70 | 67 | 65 |
| Mallinckrodt Pharmaceuticals | 46 | 52 | 66 | 54 | 70 | 50 | 56 |
| Vifor Pharma | 46 | 52 | 58 | 58 | 58 | 58 | 55 |
| Sandoz (a Novartis division) | 42 | 35 | 44 | 55 | 52 | 44 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Takeda Pharmaceutical Company Limited
- Fresenius Kabi
- Nestlé Health Science
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Fresenius Kabi | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Nestlé Health Science | ✓ | ◐ | ✓ | ◐ | ◐ | ◐ |
| AbbVie Inc. | ✓ | ✓ | − | ◐ | ◐ | ✓ |
| Baxter International Inc. | ◐ | − | ✓ | − | ✓ | − |
| Mallinckrodt Pharmaceuticals | − | − | ✓ | − | ◐ | − |
| Vifor Pharma | − | − | ◐ | ◐ | − | ◐ |
| Sandoz (a Novartis division) | − | − | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Takeda Pharmaceutical Company Limited91
2Fresenius Kabi78
3Nestlé Health Science75
4AbbVie Inc.68
5Baxter International Inc.65
6Mallinckrodt Pharmaceuticals56
7Vifor Pharma55
8Sandoz (a Novartis division)45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Takeda Pharmaceutical Company LimitedFresenius Kabi
Challenger2
Strong scale, closing on the leaders.
Nestlé Health ScienceAbbVie Inc.
Contender1
Focused players with pockets of strength.
Baxter International Inc.
Niche3
Specialists in a single segment or region.
Mallinckrodt PharmaceuticalsVifor PharmaSandoz (a Novartis division)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Short Bowel Syndrome Market — a $383M beachhead inside a $6.41B market.
Beachhead (SOM)$383Mobtainable near-term
Serviceable (SAM)$2.22Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Parenteral Nutrition
Best fit — highest urgency & budget in Treatment Type.
Economic buyer78 fit
Enteral Nutrition
Strong fit — clear ROI and a fast path to value.
End user66 fit
Pharmacological Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Cause of Short Bowel Syndrome & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Age Group
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Short Bowel Syndrome Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified24%
Evaluation13%
Closed-won6%
$10.1KCAC
$35KLTV
3.5:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Short Bowel Syndrome Market is a high-growth opportunity — $6.18B by 2033, compounding at 11.2%.
TAM · 2025$2.64Btoday
TAM · 2033$6.18Bforecast
CAGR11.2%2027–2033
Cumulative$37.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.18BTotal addressable market
SAM$2.45BServiceable available market
SOM$507MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.2% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.18BLarge & growingTAM by 2033 at 11.2% CAGR
$2.45BServiceable nowreachable with today’s model
$507MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.82BBear7.3% CAGR
$6.18BBase11.2% CAGR
$7.92BBull14.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Cause of Short Bowel Syndrome optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Short Bowel Syndrome Market — a $7.21B market by 2033. Plan: grow share from 8.8% to 17.3%.
Market size · 2033$7.21Btotal addressable
Market CAGR11.3%2027–2033
Target share17.3%from 8.8% today
Revenue ambition$1.25Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 17.3% | At risk |
| Revenue | $637M | $1.25B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 34.8% | 42.8% | On track |
| Customer retention | 89.9% | 93.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Cause of Short Bowel Syndrome capability
A defensible second engine — invest in Cause of Short Bowel Syndrome to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Cause of Short Bowel Syndrome
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $179M capacity & capability investment
- Greenlight bolt-on M&A in Cause of Short Bowel Syndrome
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Short Bowel Syndrome Market conversation — a $3.76B market you can size, segment and defend in minutes.
Market size · 2033$3.76Btotal opportunity
Growth5.8%CAGR to 2033
Addressable buyers956+accounts in scope
Typical ROI7.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.6×return on cost, year one
< 3 mopayback period
$66K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Takeda Pharmaceutical Company LimitedFresenius KabiNestlé Health ScienceAbbVie Inc.Baxter International Inc.Mallinckrodt PharmaceuticalsVifor PharmaSandoz (a Novartis division)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Short Bowel Syndrome Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Short Bowel Syndrome Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Glaucoma Treatment Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportHirsutism Treatment Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportIncontinence Care Products Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportIn Vitro Diagnostics (IVDs) Market
Market size, share, segmentation and regional forecast.
$892M market · 2025 base year
View reportDiabetes Drug Therapy Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBlood Cancer Drugs Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportBiosimilar Market
Biosimilar Market is valued at USD 12.84 Billion in 2025 and is expected to reach USD 26.83 Bil…
$12.8B market · 2025 base year
View reportCancer Therapeutics and Supportive Care Drugs Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportAxial Spondyloarthritis Treatment Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportSoft Gelatin Capsules (Softgels) Market
Market size, share, segmentation and regional forecast.
$819M market · 2025 base year
View reportPAP and Paracetamol Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportOrganic Herbal Medicine Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.